US › Healthcare

Dermata Therapeutics Inc (DRMA)

US · Healthcare · Biotechnology

$1.10+2.33%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-1.8M

Profit YoY

+19.8%

EPS

$-0.48

EPS estimate

$-0.53

EPS came in at -0.48 against a street estimate of -0.53 — a beat of 9.4%.

Key statistics

Market cap

$4.7M

Forward P/E

0.0

P/B

0.73

Book value

$1.59

EPS (TTM)

$-4.17

52-week high

$7.02

52-week low

$0.95

50-day MA

$1.27

200-day MA

$1.88

Beta

0.67

Analyst view

Analysts rate Dermata Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $4.00.

Shareholding

Insiders

24.82%

Institutions

7.38%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	1.20%
UBS Group AG	0.89%
Welch & Forbes LLC	0.50%
Mcf Advisors, LLC	0.04%
Tower Research Capital LLC	0.02%
SBI Securities Co Ltd	0.00%
Citigroup Inc	0.00%
JPMorgan Chase & Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Dermata Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.